Biotechnology - Anti-virals, ViiV Healthcare

Filter

Popular Filters

Gilead's monopoly in HIV therapies to be toppled by Viiv's Triumeq; report

Gilead's monopoly in HIV therapies to be toppled by Viiv's Triumeq; report

09-09-2014

The recent US Food and Drug Administration and European Commission approval of HIV specialist ViiV Healthcare’s…

Anti-viralsAtriplaBiotechnologyGilead SciencesGlobalDataHIVMarkets & MarketingStribildTriumeqUSAViiV Healthcare

Sales of antiretroviral agents for HIV will decline slightly over next decade

18-12-2012

Major-market sales of antiretroviral (ARV) agents for HIV will decline slightly over the next decade,…

Anti-viralsBiotechnologydolutegravirGenericsGlaxoSmithKlineGlobalMarkets & MarketingPharmaceuticalRegulationViiV Healthcare

Back to top